HIF1A and hepatocellular carcinoma: BIX01294, a G9a-specific inhibitor, decreased expression levels of HIF1α, VEGFA, proline hydroxylase 2 (PHD2), hydroxylated HIF1α and von Hippel-Lindau protein (pVHL), as well as shortened the half-life of HIF1α in HepG2 human hepatocellular carcinoma cells under hypoxic conditions.